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Abstract 
Case report on t(14;20)(q11.2;q13.3) involving the 
T-cell receptor α/δ gene in a pediatric acute 
lymphoblastic leukemia B-cell type. 
Clinics 
Age and sex: 52 years old male patient. 
Previous history: no preleukemia , no previous 
malignancy , no inborn condition of note  
Organomegaly: no hepatomegaly, no 
splenomegaly (t), no enlarged lymph nodes, no 
central nervous system involvement  
Note: A non-contributory past medical history. 
Patient had no previous leukemia or malignancy, 
and had not received chemotherapy or radiation in 
the past. 
Blood 
WBC: 1.7X 109/l 
HB: 11.3g/dl 
Platelets: 50X 109/l 
Blasts: Peripheral blood smear showed 
pancytopenia with 1% circulating myeloblasts.% 
Bone marrow: Bone marrow biopsy was 
hypercellular (90%) with dysmegakaryopoiesis, 
dysgranulopiesis, markedly increased 
erythrogenesis with dysplastic features, and 10% 
myeloblasts with no Auer rods. No metastatic 
tumor or granuloma 
Cyto-Pathology 
Classification 
Phenotype 
Findings were consistent with myelodysplastic 
syndrome, best classified as refractory anemia with 
excess blasts (RAEB-2) 
Immunophenotype 
Flow cytometric analysis of the bone marrow 
aspirate detected 5% myeloblasts with dim 
expression of CD45. Blasts were positive for CD13, 
CD33, CD34, CD117, CD38, and HLA-DR. 
Erythroid precursors constituted 55% of the gated 
cells and were positive for CD36 and glycophorin 
A. 
Diagnosis Myelodysplastic syndrome, RAEB-2 
Survival 
Date of diagnosis 01-2015 
Treatment 
In January 2015, the patient received high dose 
Ara-C chemotherapy followed by multiple doses of 
Vidaza. In December 2015, he underwent 
allogeneic peripheral blood stem cell transplant 
from a matched-unrelated female donor. 
Complete remission: no   
Treatment related death: yes 
Status Dead 80 days after transplant 
Survival 15 months 
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Karyotype 
Sample Bone marrow aspirate 
Culture time 24 hours unstimulated culture; 48 
hours with 10% conditioned media 
Banding G- banding 
Results 
Two unrelated clones were identified:  
clone 1 44-47,Y,inv(X)(p21p22.1), del(7)(p11.2), 
add(7)(q21),+der(?)r(7)amp(q31), del(9)(p22),-13, 
add(16)(p12), add(19)(p13.2)[cp16]  
clone 2 46,XY,del(5)(q13q33),add(20)(q11.2)[3] 
Other molecular cytogenetics results 
Fluorescence in situ hybridization (FISH) was 
performed on the pellet from the harvested bone 
marrow specimen using the MDS panel DNA 
probes that included D5S23:D5S721/5p15.2, 
EGR1/5q31, D7Z1/CEP-7, D7S486/7q31, 
D8Z2/CEP-8, and D20S108/20q12. Results of 
FISH revealed an amplification the D7S486 /7q31 
region in approximately 60% of cells (>6 copies per 
nucleus), and deletions of EGR1/5q and 20q12 in 
10% of cells.  In addition, we investigated the status 
of MET as a candidate oncogene for the amplified 
7q31 region.  
Accordingly, the LSI MET SpectrumRed probe 
along with CEP-7 SpectrumGreen as a control were 
hybridized on the same specimen.  
The LSI MET probe is approximately 456 kb and 
contains the entire MET gene on chromosome 
7q31.2. The hybridization revealed amplification of 
the MET gene with only 2 signals/copies for the 
control CEP-7 (Figure 2). All FISH probes were 
purchased from Abbott Molecular, Downers Grove 
IL, USA. 
 
Figure 1: G-banded karyotype at time of diagnosis showing multiple abnormalities including a ring chromosome, and other 
unbalanced aberrations 
 
Figure 2: FISH with LSI MET SepectrumRed probe showing multiple red signals for MET while two green signals for centromere 
7, On metaphase cells the red signals hybridized to the ring chromosome. 
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Comments 
Gene amplification in leukemia is relatively rare, 
mostly reported for the MLL and CMYC 
oncogenes. However, MET amplification has not 
been reported in leukemia. Here, we report the first 
case of MDS with MET amplification in the form 
of a ring chromosome. The patient was a 52-year-
old male who initially presented with shortness of 
breath and fatigue during the latter part of 
December 2014. A CBC was performed at this time 
and revealed marked leukopenia, anemia, and 
thrombocytopenia. Upon arrival to our facility, 
assessment of bone marrow biopsy and aspirate 
revealed dysplastic changes consistent with the 
diagnosis of myelodysplastic syndrome (MDS), 
classified as RAEB-2. Chromosomal analysis at 
that time revealed at least two unrelated clones; the 
dominant clone presented with multiple unbalanced 
chromosomal rearrangements, and extreme 
karyotypic heterogeneity. However, the most 
notable chromosomal aberrations were additional 
genetic material on chromosomes 7q, 16p and 19p, 
a large ring that appeared to be derived from 
chromosome 7, and an inversion of Xp. Clone 2, 
was a minor clone and showed 5q and 20q 
deletions, the classic abnormalities for MDS. FISH 
demonstrated deletions of EGR1/5q31 and 20q12 in 
8-12% of cells, but unexpectedly amplification of 
the 7q31 region was noticed in 60% of cells. The 
FISH probe, D7S486/7q31, spans a region of 
306kb, which contains several tumor suppressor 
genes such as MDFIC, TES, CAV1. The closest 
candidate oncogene to D7S486 region at 7q31 is the 
MET gene. Therefore, MET/7q31.2 probe was 
hybridized to the same specimen that confirmed an 
amplification of MET oncogene. In metaphase 
cells, the amplified signals are located on the ring 
chromosome which lacks a centromere 7 signal 
(Figure 2).  
The MET gene encodes a tyrosine kinase receptor 
for the hepatocyte growth factor (HGF). Whereas 
the physiological expression of MET is essential for 
wound healing and embryonic development, 
aberrant overexpression of MET results in up-
regulation of cell proliferation, motility, migration, 
invasion, and survival. MET MET activating 
mutations and gene amplification have been 
identified in a variety of solid tumors including, 
gastric, pharynx, colon, lung, and breast cancer. 
Further studies have shown that inhibition of MET 
signaling pathways has led to inhibition of growth, 
migration and invasion. For these reasons MET has 
become a valuable target for cancer therapy and 
several drugs targeting MET and its ligand HGF are 
being evaluated in clinical trials in various cancers. 
The MET gene is also overexpressed in 
hematological malignancies. The most recent 
studies on multiple myeloma showed that the 
HGF/MET pathway is constitutively active in 
plasma cells of myeloma patients and it confers 
multidrug resistance. These findings were also true 
for acute myeloid leukemia (AML).  
Studies of samples taken from AML patients and 
cell lines revealed that MET is activated in 
leukemic cells as a result of aberrant autocrine 
signaling by HGF, and inhibition of this autocrine 
activation loop would inhibit the growth and 
survival of these cells.  
Other genes of significance within the region of 
chromosome 7q31 include MDFIC, TFEC, TES, 
CAV-1, CAV-2, and ST7.  
These genes have been implicated in various 
malignancies but their role has not yet been fully 
elucidated. TES, CAV-1, CAV-2, and ST7 are 
considered candidate tumor suppressors implicated 
in numerous malignancies.  
MDFIC, also known as HIC, is frequently deleted 
in myeloid malignancies. TFEC is a member of the 
microphthalmia family of transcription factors 
whose dysregulation may have a role in renal cell 
carcinoma, melanoma, and sarcoma. 
Despite aggressive therapy, our patient never 
achieved remission, and he died from disease 
progression shortly after transplant.   
The complex karyotype as well as MET 
amplification certainly contributes to the dismal 
sequence of the disease. Therapeutic agents 
targeting the MET pathway may help improve 
patient survival. 
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